University Of Iowa Hosp & Clinics

Type: Teaching hospital
Where: Iowa City, IA
Medicare CCN: 160058
Received: $18,086,765 in 2,550 records, 2020 ($842,357 general, $17,244,407 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2020	General payment	332	$842,357
2020	Research payment	2,218	$17,244,407

By company

Company	Records	Amount	Years
PFIZER INC.	91	$3,693,622	2020
VERTEX PHARMACEUTICALS INCORPORATED	8	$1,158,492	2020
Merck Sharp & Dohme LLC	287	$1,149,192	2020
Gilead Sciences, Inc.	46	$1,053,998	2020
ABBVIE INC.	54	$636,628	2020
Sarepta Therapeutics, Inc.	20	$568,208	2020
Regeneron Pharmaceuticals, Inc.	40	$530,361	2020
Novartis Pharmaceuticals Corporation	13	$505,028	2020
KCI USA, Inc.	2	$437,125	2020
AstraZeneca Pharmaceuticals LP	33	$417,216	2020
F. Hoffmann-La Roche AG	5	$368,091	2020
Takeda Pharmaceuticals U.S.A., Inc.	63	$357,717	2020
Genentech, Inc.	57	$305,271	2020
Janssen Research & Development, LLC	50	$304,805	2020
MED-EL Corporation	5	$290,994	2020
bioMerieux Inc	1	$284,304	2020
Zimmer Biomet Holdings, Inc.	8	$272,031	2020
Eli Lilly and Company	14	$252,847	2020
Novo Nordisk AS	492	$251,969	2020
Incyte Corporation	118	$243,548	2020
Allergan, Inc.	51	$240,120	2020
Amgen Inc.	52	$238,373	2020
GENZYME CORPORATION	32	$229,738	2020
Dynavax Technologies Corporation	14	$214,584	2020
BAUDAX BIO INC.	9	$210,303	2020
E.R. Squibb & Sons, L.L.C.	18	$194,643	2020
Boston Scientific Corporation	47	$194,249	2020
Intercept Pharmaceuticals, Inc.	22	$168,024	2020
Cochlear Americas	16	$162,065	2020
Roche TCRC, Inc.	20	$160,619	2020
Medtronic USA, Inc.	5	$156,174	2020
Kite Pharma, Inc.	21	$151,622	2020
Bayer Healthcare Pharmaceuticals Inc.	76	$142,180	2020
Boehringer Ingelheim Pharmaceuticals, Inc.	12	$140,712	2020
New York Blood Center, Inc.	1	$106,746	2020
Roche Diagnostics Operations, Inc.	2	$106,216	2020
Abbott Laboratories	17	$96,590	2020
United Therapeutics Corporation	27	$93,896	2020
Pharmacyclics LLC, an AbbVie Company	17	$93,326	2020
BeiGene, Ltd.	2	$90,168	2020
SANOFI US SERVICES INC.	9	$87,069	2020
Siemens Medical Solutions USA, Inc.	3	$86,295	2020
Medicure Pharma Inc.	2	$66,946	2020
GW Research Limited	2	$66,898	2020
Advanced Bionics, LLC	1	$66,340	2020
MicroVention, Inc.	5	$61,390	2020
Clovis Oncology, Inc.	9	$58,350	2020
Stryker Corporation	4	$55,380	2020
Medical Device Business Services, Inc.	4	$53,875	2020
Terumo BCT, Inc.	6	$53,564	2020

By nature of payment

Nature	Records	Amount
Research payment	2,218	$17,244,407
Grant	23	$302,198
Royalty or License	45	$283,861
Space rental or facility fees (teaching hospital only)	155	$110,752
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	71	$51,471
Consulting Fee	16	$39,221
Gift	3	$30,614
Education	9	$20,617
Charitable Contribution	9	$2,864
Travel and Lodging	1	$753

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Allergan, Inc.	$51,911	Research payment	In-kind items and services		AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o	2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$40,250	Research payment	Cash or cash equivalent	Artis Q Device, AT - Fixed interventional x-ray/angiography fluoroscopy	Iowa Ortega Neuro Clinical AT	2020
2020-12-31	Stryker Corporation	$29,605	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-31	Diagnostica Stago, Inc	$26,081	Research payment	In-kind items and services	Device, Global Hemostasis		2020
2020-12-31	Edwards Lifesciences Corporation	$18,027	Research payment	Cash or cash equivalent		Magna Mitral 2006-05	2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$16,433	Research payment	Cash or cash equivalent	SOMATOM Force Device, CT and RO incl. Computed Tomography and Radiation Oncology	Functional Lung Imaging with Dualenergy CT	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$11,169	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co	2020
2020-12-31	KARL STORZ Endoscopy-America	$5,243	Research payment	In-kind items and services	PDD System Device, UROLOGY	Blue Light Flexible Cystoscopy with Cysview Study	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$4,784	Research payment	In-kind items and services	EPANOVA Drug, Cardiovascular and Metabolism	A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi	2020
2020-12-31	Boehringer Ingelheim Pharma GmbH & Co.KG	$1,524	Research payment	In-kind items and services	TRADJENTA Drug, DIABETES	52 wks Eff. & Saf. Ph III in Paediatrics	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$803	Research payment	In-kind items and services	FARXIGA Drug, Cardiovascular and Metabolism	A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic	2020
2020-12-31	Masimo Corporation	$767	Education	In-kind items and services	rainbow Acoustic Monitoring Device, Devices		2020
2020-12-31	Allergan, Inc.	$630	Research payment	In-kind items and services		A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli	2020
2020-12-31	Horizon Therapeutics plc	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ACTIMMUNE Drug, ACTIMMUNE		2020
2020-12-31	Allergan, Inc.	$459	Research payment	In-kind items and services		A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli	2020
2020-12-31	Linvatec Corporation	$98	Grant	In-kind items and services	LINVATEC KNEE PRESERVATION SYSTEM Device, ORTHOPEDIC SURGERY		2020
2020-12-31	Allergan, Inc.	$87	Research payment	In-kind items and services		A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Di	2020
2020-12-30	Merck Sharp & Dohme LLC	$2,586	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2020
2020-12-30	ABBVIE INC.	$2,252	Research payment	Cash or cash equivalent		M17-327	2020
2020-12-30	ABBVIE INC.	$2,160	Research payment	Cash or cash equivalent	RINVOQ Drug, IMMUNOLOGY	M14-533	2020
2020-12-29	Zimmer Biomet Holdings, Inc.	$75,292	Royalty or License	Cash or cash equivalent	Trabecular Metal (TM) Ankle Device, Foot & Ankle		2020
2020-12-29	United Therapeutics Corporation	$4,926	Research payment	Cash or cash equivalent	TYVASO Drug, PAH	A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST	2020
2020-12-28	Clovis Oncology, Inc.	$3,225	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro	2020
2020-12-25	PFIZER INC.	$10,000	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-24	Regeneron Pharmaceuticals, Inc.	$259,898	Research payment	Cash or cash equivalent		A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo	2020
2020-12-24	Pharmacyclics LLC, an AbbVie Company	$21,124	Research payment	Cash or cash equivalent	Imbruvica Drug, Oncology	PCYC-1128-CA	2020
2020-12-24	Regeneron Pharmaceuticals, Inc.	$10,052	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS	2020
2020-12-24	Alexion Pharmaceuticals, Inc.	$4,725	Research payment	Cash or cash equivalent		An Observational, Non-interventional, Long-Term Registry of Patients with Generalized Myasthenia Gravis Treated with Sol	2020
2020-12-24	Amgen Inc.	$3,000	Research payment	Cash or cash equivalent		AMG 510 - Adv. KRAS G12C solid tumors_20190135	2020
2020-12-24	Deciphera Pharmaceuticals Inc.	$1,655	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-24	Deciphera Pharmaceuticals Inc.	$1,265	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-23	Gilead Sciences, Inc.	$8,861	Research payment	Cash or cash equivalent		Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib	2020
2020-12-23	Gilead Sciences, Inc.	$2,877	Research payment	Cash or cash equivalent		A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease	2020
2020-12-23	PFIZER INC.	$2,625	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2020
2020-12-23	Allergan, Inc.	$2,394	Research payment	Cash or cash equivalent		AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o	2020
2020-12-23	Penumbra, Inc.	$900	Research payment	Cash or cash equivalent	Artemis Device, Neurosurgery	MIND	2020
2020-12-23	SEAGEN INC.	$225	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the	2020
2020-12-23	Boehringer Ingelheim France S.A.S.	$218	Research payment	In-kind items and services	TRADJENTA Drug, DIABETES	52 wks Eff. & Saf. Ph III in Paediatrics	2020
2020-12-22	Genentech, Inc.	$74,052	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	A PHASE I II STUDY OF IDASANUTLIN PLUS CHEMOTHERAPY IN 1L FIT AML	2020
2020-12-22	Novo Nordisk AS	$12,244	Research payment	Cash or cash equivalent	Esperoct Biological, Hemophilia	NN7088-4410	2020
2020-12-22	Novo Nordisk AS	$9,447	Research payment	Cash or cash equivalent		EX9536-4388	2020
2020-12-22	Novo Nordisk AS	$8,818	Research payment	Cash or cash equivalent		NN7769-4513	2020
2020-12-22	Kite Pharma, Inc.	$8,127	Research payment	Cash or cash equivalent	Yescarta Drug, CELLT	A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera	2020
2020-12-22	Novo Nordisk AS	$6,678	Research payment	Cash or cash equivalent		NN7769-4513	2020
2020-12-22	Merck Sharp & Dohme LLC	$4,099	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224	2020
2020-12-22	Novo Nordisk AS	$3,626	Research payment	Cash or cash equivalent	Sogroya Biological, Growth Hormone	NN8640-4263	2020
2020-12-22	Incyte Corporation	$3,497	Research payment	Cash or cash equivalent		A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$2,275	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$2,275	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$2,275	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$2,275	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Novo Nordisk AS	$1,638	Research payment	Cash or cash equivalent		NN7769-4513	2020
2020-12-22	Novo Nordisk AS	$945	Research payment	Cash or cash equivalent		EX9536-4388	2020
2020-12-22	Novo Nordisk AS	$650	Research payment	Cash or cash equivalent		NN7769-4513	2020
2020-12-22	Novo Nordisk AS	$630	Research payment	Cash or cash equivalent	Esperoct Biological, Hemophilia	NN7088-4410	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$490	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$490	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$490	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$490	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Bayer Healthcare Pharmaceuticals Inc.	$490	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2020
2020-12-22	Merck Sharp & Dohme LLC	$232	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224	2020
2020-12-22	Novo Nordisk AS	$200	Research payment	Cash or cash equivalent		EX9536-4388	2020
2020-12-22	Novo Nordisk AS	$137	Research payment	Cash or cash equivalent	Esperoct Biological, Hemophilia	NN7088-4410	2020
2020-12-21	F. Hoffmann-La Roche AG	$138,731	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	GENOME-WIDE CRISPRCAS9 SCREEN TO IDENTIFY HOST FACTORS ESSENTIAL FOR THE REPLICATION OF RESPIRATORY VIRUSES	2020
2020-12-21	Gilead Sciences, Inc.	$47,494	Research payment	Cash or cash equivalent	Veklury Drug, COVID-19	The Simple Study in Coronavirus, Severe Subjects	2020
2020-12-21	Merck Sharp & Dohme LLC	$26,055	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv	2020
2020-12-21	Clovis Oncology, Inc.	$25,975	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)	2020
2020-12-21	Janssen Research & Development, LLC	$20,308	Research payment	Cash or cash equivalent		Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential,	2020
2020-12-21	Boston Scientific Corporation	$9,250	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	PROTECTED TAVR	2020
2020-12-21	Merck Sharp & Dohme LLC	$6,527	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection	2020
2020-12-21	Esperion Therapeutics, Inc.	$218	Research payment	Cash or cash equivalent	NEXLETOL Drug, ANTILIPEMIC AGENTS	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC	2020
2020-12-21	Esperion Therapeutics, Inc.	$218	Research payment	Cash or cash equivalent	NEXLETOL Drug, ANTILIPEMIC AGENTS	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC	2020
2020-12-21	Esperion Therapeutics, Inc.	$150	Research payment	Cash or cash equivalent	NEXLETOL Drug, ANTILIPEMIC AGENTS	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC	2020
2020-12-21	PFIZER INC.	$150	Research payment	Cash or cash equivalent	BRAFTOVI Drug, ONCOLOGY	A MULTICENTER RANDOMIZED OPENLABEL 3ARM PHASE 3 STUDY OF ENCORAFENIB CETUXIMAB PLUS OR MINUS BINIMETINIB VS IRINOTECANC	2020
2020-12-19	Merck Sharp & Dohme LLC	$37	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2020
2020-12-18	PFIZER INC.	$10,044	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-18	Sarepta Therapeutics, Inc.	$9,851	Research payment	Cash or cash equivalent	Exondys 51 Drug, Genetic Disease	4658-301	2020
2020-12-18	Sarepta Therapeutics, Inc.	$9,851	Research payment	Cash or cash equivalent	Exondys 51 Drug, Genetic Disease	4658-301	2020
2020-12-18	Genentech, Inc.	$8,425	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	FAP IL2V FP CHECKPOINT INHIBITOR COMBINATION STUDY	2020
2020-12-18	Janssen Research & Development, LLC	$5,075	Research payment	Cash or cash equivalent		Uptravi (Selexipag): the users drug registry	2020
2020-12-18	Elekta, Inc.	$800	Consulting Fee	Cash or cash equivalent	Unity Device, ELEKTA LINEAR ACCELERATOR (MR)		2020
2020-12-17	Edwards Lifesciences Corporation	$9,926	Research payment	Cash or cash equivalent		Early-TAVR Trial #2016-07	2020
2020-12-17	Medtronic USA, Inc.	$5,889	Research payment	Cash or cash equivalent	CD HORIZON Device, TL	Investigator Sponsored Research	2020
2020-12-17	Merck Sharp & Dohme LLC	$2,701	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The	2020
2020-12-17	Merck Sharp & Dohme LLC	$1,880	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv	2020
2020-12-17	PFIZER INC.	$1,500	Research payment	Cash or cash equivalent		A PHASE I OPEN LABEL STUDY TO EVALUATE THE SAFETY PHARMACOKINETIC PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF06863135 A	2020
2020-12-17	Janssen Research & Development, LLC	$574	Research payment	Cash or cash equivalent		An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression	2020
2020-12-17	Boehringer Ingelheim Pharma GmbH & Co.KG	$220	Research payment	In-kind items and services		Emphysema Progression Biomarker Study	2020
2020-12-16	Genentech, Inc.	$1,595	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC	2020
2020-12-16	GENZYME CORPORATION	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	DUPIXENT Biological, Immunology		2020
2020-12-16	Merck Sharp & Dohme LLC	$275	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2020
2020-12-15	PFIZER INC.	$1,614	Research payment	Cash or cash equivalent		A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651	2020
2020-12-15	Merck Sharp & Dohme LLC	$113	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2020
2020-12-14	Janssen Research & Development, LLC	$10,324	Research payment	Cash or cash equivalent		A Prospective, Multicenter, non-Interventional Study for the Identification of Biomarker Signatures for the early detect	2020
2020-12-14	Janssen Research & Development, LLC	$4,613	Research payment	Cash or cash equivalent		Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential,	2020
2020-12-14	ABBVIE INC.	$4,225	Research payment	Cash or cash equivalent		M19-530	2020
2020-12-14	Travere Therapeutics, Inc.	$2,595	Research payment	Cash or cash equivalent		DUET	2020
2020-12-14	GENZYME CORPORATION	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	DUPIXENT Biological, Immunology		2020
2020-12-13	AstraZeneca Pharmaceuticals LP	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	FASENRA Drug, Respiratory		2020
2020-12-11	ABBVIE INC.	$38,972	Research payment	Cash or cash equivalent	RINVOQ Drug, IMMUNOLOGY	M14-234	2020
2020-12-11	PFIZER INC.	$4,087	Research payment	Cash or cash equivalent		A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC	2020
2020-12-11	Elekta, Inc.	$3,600	Consulting Fee	Cash or cash equivalent	Unity Device, ELEKTA LINEAR ACCELERATOR (MR)		2020
2020-12-11	Elekta, Inc.	$3,600	Consulting Fee	Cash or cash equivalent	Unity Device, ELEKTA LINEAR ACCELERATOR (MR)		2020
2020-12-11	Elekta, Inc.	$3,600	Consulting Fee	Cash or cash equivalent	Unity Device, ELEKTA LINEAR ACCELERATOR (MR)		2020
2020-12-10	Genentech, Inc.	$22,029	Research payment	Cash or cash equivalent	Xolair Biological, Immunology	USING OBJECTIVE PATIENT CENTRIC MEASURES TO SHOW IMPACT OF OMALIZUMAB ON ASTHMA IMPROVEMENT	2020
2020-12-10	Novo Nordisk AS	$200	Research payment	Cash or cash equivalent		EX9536-4388	2020
2020-12-09	Medicure Pharma Inc.	$15,000	Research payment	Cash or cash equivalent	Aggrastat (Tirofiban-HCI) Drug, Cardiology	Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)	2020
2020-12-09	Clovis Oncology, Inc.	$9,345	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$2,795	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$2,795	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	KLS-Martin L.P.	$2,500	Grant	Cash or cash equivalent			2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$2,044	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$1,549	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Mallinckrodt Hospital Products Inc.	$1,500	Research payment	Cash or cash equivalent		STRATAGRAFT SKIN TISSUE IN THE PROMOTION OF AUTOLOGOUS SKIN REGENERATION OF COMPLEX SKIN DEFECTS DUE TO THERMAL BURNS TH	2020
2020-12-09	Mallinckrodt Hospital Products Inc.	$1,199	Research payment	Cash or cash equivalent		STRATAGRAFT SKIN TISSUE IN THE PROMOTION OF AUTOLOGOUS SKIN REGENERATION OF COMPLEX SKIN DEFECTS DUE TO THERMAL BURNS TH	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$258	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$150	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$150	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$150	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$150	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$150	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Medtronic USA, Inc.	$135	Research payment	In-kind items and services	CD HORIZON Device, TL	Investigator Sponsored Research	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$76	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$75	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$75	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$58	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$58	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$58	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$58	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-09	Deciphera Pharmaceuticals Inc.	$47	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE	2020
2020-12-08	BIOTRONIK INC.	$3,750	Grant	Cash or cash equivalent			2020
2020-12-08	F. Hoffmann-La Roche AG	$763	Research payment	Cash or cash equivalent	Tarceva Drug, BioOncology	1L NSCLC DX ALL COMER SQUAMOUS	2020
2020-12-08	Genentech, Inc.	$606	Research payment	Cash or cash equivalent	Herceptin Biological, BioOncology	CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB	2020
2020-12-08	BIOTRONIK INC.	$302	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$252	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$252	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$245	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$245	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	Merck Sharp & Dohme LLC	$132	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2020
2020-12-08	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2020
2020-12-08	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2020
2020-12-08	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	BIOTRONIK INC.	$25	Research payment	Cash or cash equivalent		BIO-LIBRA	2020
2020-12-08	Incyte Corporation	$21	Research payment	Cash or cash equivalent		A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin	2020

The latest 200 records of 2,550.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Iowa City, IA, county Johnson County, IA, state Iowa; placed by its city name.

Measure	Place (city or town) Iowa City, IA	County Johnson County, IA	State Iowa
Population B01003	75,752	156,639	3,210,507
Population, 2020 census P1	74,828	152,854	3,190,369
Median age B01002	26.2	31.0	38.6
Under 18 B01001	14.3%	19.3%	22.9%
65 and over B01001	12.3%	13.3%	18.1%
Households B11001	30,816	63,341	1,315,707
Foreign born B05002	12.2%	9.8%	5.9%
Median household income B19013	$58,546	$74,935	$75,059
Median family income B19113	$111,960	$118,607	$97,491
Per capita income B19301	$37,842	$45,136	$40,877
Poverty rate B17001	26.3%	17.1%	11.1%
Unemployment rate B23025	4.6%	3.8%	3.6%
Civilian labor force B23025	45,244	90,024	1,699,994
Mean commute (minutes) B08013	17.3	19.4	19.8
Bachelor's degree or higher B15003	60.5%	55.2%	31.4%
Housing units B25001	33,863	68,217	1,437,699
Owner-occupied B25003	47.2%	59.4%	71.7%
Renters B25003	52.8%	40.6%	28.3%
Median home value B25077	$285,900	$308,600	$208,000
Median gross rent B25064	$1,094	$1,122	$972
White, not Hispanic B03002	70.4%	74.8%	82.3%
Black B03002	9.4%	7.6%	3.8%
Hispanic or Latino B03002	8.1%	6.7%	7.3%
Asian B03002	7.1%	5.6%	2.5%
American Indian and Alaska Native B03002	0.0%	0.1%	0.2%

Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Iowa City, IA.